285 related articles for article (PubMed ID: 29678523)
1. Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX).
Grønhøj C; Jensen DH; Vester-Glowinski P; Jensen SB; Bardow A; Oliveri RS; Fog LM; Specht L; Thomsen C; Darkner S; Jensen M; Müller V; Kiss K; Agander T; Andersen E; Fischer-Nielsen A; von Buchwald C
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):581-592. PubMed ID: 29678523
[TBL] [Abstract][Full Text] [Related]
2. First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial.
Grønhøj C; Jensen DH; Glovinski PV; Jensen SB; Bardow A; Oliveri RS; Specht L; Thomsen C; Darkner S; Kiss K; Fischer-Nielsen A; von Buchwald C
Trials; 2017 Mar; 18(1):108. PubMed ID: 28270226
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial.
Jakobsen KK; Carlander AF; Todsen T; Melchiors J; Paaske N; Østergaard Madsen AK; Kloch Bendtsen S; Mordhorst C; Stampe H; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggaard CD; Werner Hauge A; Christensen R; Grønhøj C; von Buchwald C
Clin Cancer Res; 2024 May; 30(10):2078-2084. PubMed ID: 38441659
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study.
Jakobsen KK; Carlander AF; Grønhøj C; Todsen T; Melchiors J; Paaske N; Madsen AKØ; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggard CD; von Buchwald C
Trials; 2023 Sep; 24(1):567. PubMed ID: 37658468
[TBL] [Abstract][Full Text] [Related]
5. Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial.
Lynggaard CD; Grønhøj C; Jensen SB; Christensen R; Specht L; Andersen E; Andersen TT; Ciochon UM; Rathje GS; Hansen AE; Stampe H; Fischer-Nielsen A; von Buchwald C
Clin Cancer Res; 2022 Jul; 28(13):2890-2897. PubMed ID: 35486613
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 clinical study of cell therapy with effective-mononuclear cells (E-MNC) for radiogenic xerostomia (first-in-human study) (FIH study on E-MNC therapy for radiogenic xerostomia).
Sumita Y; Iwamoto N; Seki M; Yoshida T; Honma R; Iwatake M; Ohba S; Takashi I; Hotokezaka Y; Harada H; Kuroshima S; Nagai K; Asahara T; Atsushi Kawakam I; Asahina I
Medicine (Baltimore); 2020 Jun; 99(26):e20788. PubMed ID: 32590759
[TBL] [Abstract][Full Text] [Related]
7. Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II).
Lynggaard CD; Grønhøj C; Christensen R; Fischer-Nielsen A; Melchiors J; Specht L; Andersen E; Mortensen J; Oturai P; Barfod GH; Haastrup EK; Møller-Hansen M; Haack-Sørensen M; Ekblond A; Kastrup J; Jensen SB; von Buchwald C
Stem Cells Transl Med; 2022 May; 11(5):478-489. PubMed ID: 35435231
[TBL] [Abstract][Full Text] [Related]
8. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia.
Blitzer GC; Glazer T; Burr A; Gustafson S; Ganz O; Meyers R; McDowell KA; Nickel KP; Mattison RJ; Weiss M; Chappell R; Rogus-Pulia NM; Galipeau J; Kimple RJ
Cytotherapy; 2023 Nov; 25(11):1139-1144. PubMed ID: 37589639
[TBL] [Abstract][Full Text] [Related]
9. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction.
Blitzer GC; Rogus-Pulia NM; Mattison RJ; Varghese T; Ganz O; Chappell R; Galipeau J; McDowell KA; Meyers RO; Glazer TA; Kimple RJ
Cytotherapy; 2022 May; 24(5):534-543. PubMed ID: 35183442
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology and management of radiation-induced xerostomia.
Berk LB; Shivnani AT; Small W
J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal Stromal/Stem Cell Therapy Improves Salivary Flow Rate in Radiation-Induced Salivary Gland Hypofunction in Preclinical in vivo Models: A Systematic Review and Meta-Analysis.
Carlander AF; Gundestrup AK; Jansson PM; Follin B; Hoeeg C; Kousholt BS; Larsen RT; Jakobsen KK; Rimborg S; Fischer-Nielsen A; Grønhøj C; Buchwald CV; Lynggaard CD
Stem Cell Rev Rep; 2024 May; 20(4):1078-1092. PubMed ID: 38430363
[TBL] [Abstract][Full Text] [Related]
12. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours.
Liem IH; Olmos RA; Balm AJ; Keus RB; van Tinteren H; Takes RP; Muller SH; Bruce AM; Hoefnagel CA; Hilgers FJ
Eur J Nucl Med; 1996 Nov; 23(11):1485-90. PubMed ID: 8854847
[TBL] [Abstract][Full Text] [Related]
13. Impact of submandibular gland excision on salivary gland function in head and neck cancer patients.
Jaguar GC; Lima EN; Kowalski LP; Pellizon AC; Carvalho AL; Alves FA
Oral Oncol; 2010 May; 46(5):349-54. PubMed ID: 20227906
[TBL] [Abstract][Full Text] [Related]
14. The role of stem cells in the prevention and treatment of radiation-induced xerostomia in patients with head and neck cancer.
Nevens D; Nuyts S
Cancer Med; 2016 Jun; 5(6):1147-53. PubMed ID: 26880659
[TBL] [Abstract][Full Text] [Related]
15. Diffusion-weighted imaging as a follow-up modality for evaluation of major salivary gland function in nasopharyngeal carcinoma patients: a preliminary study.
Fan WJ; Teng F; Luo YR; Yu W; Zhang Q; Lu YP; Ma L
Strahlenther Onkol; 2020 Jun; 196(6):530-541. PubMed ID: 32025803
[TBL] [Abstract][Full Text] [Related]
16. Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study.
Forner L; Hyldegaard O; von Brockdorff AS; Specht L; Andersen E; Jansen EC; Hillerup S; Nauntofte B; Jensen SB
Oral Oncol; 2011 Jun; 47(6):546-51. PubMed ID: 21493124
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.
Vissink A; Mitchell JB; Baum BJ; Limesand KH; Jensen SB; Fox PC; Elting LS; Langendijk JA; Coppes RP; Reyland ME
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):983-91. PubMed ID: 20970030
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and safety of acupuncture in the treatment of irradiation-induced xerostomia in patients with head and neck cancer: a systematic review.
O'Sullivan EM; Higginson IJ
Acupunct Med; 2010 Dec; 28(4):191-9. PubMed ID: 21062848
[TBL] [Abstract][Full Text] [Related]
19. Dramatic and prolonged decrease of whole salivary secretion in nasopharyngeal carcinoma patients treated with radiotherapy.
Jen YM; Lin YC; Wang YB; Wu DM
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Mar; 101(3):322-7. PubMed ID: 16504865
[TBL] [Abstract][Full Text] [Related]
20. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
